Tocilizumab for Relapsing Polychondritis

Status Withdrawn

Clinical Trial Summary

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Relapsing Polychondritis

Clinical Trial Details

NCT number	NCT01104480
Study type	Interventional
Source	McMaster Children's Hospital
Contact
Status	Withdrawn
Phase	Phase 2
Start date	May 2010
Completion date	May 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02257866` - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Completed	`NCT04077736` - Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis	Phase 2
Active, not recruiting	`NCT05168475` - Biologics in Refractory Vasculitis	Phase 2
Completed	`NCT01272856` - Study on the Safety of Abatacept in Relapsing Polychondritis	Phase 1
Completed	`NCT01041248` - Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab	N/A
Recruiting	`NCT04919538` - Longitudinal Study for Relapsing Polychondritis
Recruiting	`NCT06019221` - Pediatric Relapsing Polychondritis : Diagnosis and Management in a French Retrospective Study
Recruiting	`NCT03840928` - PatientSpot Formerly Known as ArthritisPower